

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Uhlmann et al.

Appl. No. 09/500,991

Filed: February 15, 2000

For: Compounds Modulating Sister

**Chromatid Separation and Method** 

for Identifying Same

Confirmation No.

Art Unit: 1652

Examiner: Fronda, C.

Atty. Docket: 0652.2040000/EKS/Y-W

## First Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on August 3, 2000 in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

middle A. Carilla

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Fig. No. 3385/ Eric K. Steffe

Attorney for Applicants Registration No. 36,688

Date: February 28, 2002

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

P:\USERS\YWANG\0652\2040000\IDS

SKGF Rev. 1/26/01 mac

Page 1 of 1

FORM PTO-1449

## FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 0652.2040000/EKS/Y-W	APPLICATION NO. 09/500,991				
APPLICANT UHLMANN et al.					
FILING DATE	GROUP				

EVANGER		<u> </u>		т	U.S. PATENT DOCUMENTS		<del></del>		<del></del>	
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE	
	AA1	10/	051,311	pending	Peters et al.				01/22/02	
	AB1									
	AC1									
	AD1									
	AE1			<u> </u>						
	AF1			ļ.,						
	AG1			<u> </u>						
	AH1									
	AI1				,					
	AJ1									
	AK1			1		<u>-</u> -				
				FO	REIGN PATENT DOCUMENTS					
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION	
	AL1								Yes No	
	AM1								Yes	
									No Yes	
	AN1								No	
	AO1								Yes No	
	AP1								Yes No	
			OTHER (	Including Aut	hor, Title, Date, Pertinent	Pages	etc.)		NO	
	AR	1								
	AS	1								
	AT	1								
EXAMINER							DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.